Bing

SEARCH HISTORY

GlaxoSmithKline plc (NYSE:GSK)‘s stock had its “hold” rating reissued by Berenberg Bank in a research note issued on Friday. Several other analysts have also recently commented on the stock. Analysts at Bank of America reiterated an …
Mideast Times · 9 hours ago
GlaxoSmithKline plc
GlaxoSmithKline plc (NYSE:GSK)‘s stock had its “underperform” rating reiterated by stock analysts at Credit Suisse in a report issued on Friday. Shares of GlaxoSmithKline plc (NYSE:GSK) traded down 0.1688% during mid-day trading on Friday ...
Ticker Report · 9 hours ago
GlaxoSmithKline plc
Bob Ciura: Dividend stocks are abundant within the highly profitable health care and pharmaceutical sectors. But the biggest dividend among Big Pharma stocks belongs to GlaxoSmithKline PLC (NYSE:GSK). The …
ETF Daily News · 5/21/2015
GlaxoSmithKline plc
More from Bing News
GlaxoSmithKline recently completed a deal that made it one ... Don't be too late to the party -- click here for one stock to own when the Web goes dark.
Investopedia · 8 hours ago
Pfizer
In-depth coverage >
GlaxoSmithKline plc (LON:GSK)‘s stock had its “underperform” rating reaffirmed by analysts at Bank of America in a research report issued to clients and investors on Wednesday. They currently have a GBX 1,450 ($22.81) target price on the stock.
wkrb13.com · 1 day ago
Stock analysts at Citigroup Inc. started coverage on shares of GlaxoSmithKline plc (NYSE:GSK) in a report issued on Wednesday. The firm set a “neutral” rating on the stock. Several other analysts have also recently commented on the stock. Analysts …
sleekmoney.com · 1 day ago
Dividend stocks are undoubtedly powerful investing vehicles that can greatly amplify gains over a long period of time. That said, it's no easy feat to pick the right dividend stocks for your portfolio. Within the healthcare …
The Motley Fool · 5/13/2015
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer TheStreet Ratings' stock model projects a stock's total return potential ...
The Street · 11 hours ago
... deal with GlaxoSmithKline ($GSK) or another run on AstraZeneca ($AZN) being bandied about as the likely options. Either would cut Pfizer's tax rate and give it some products to salve its various ills, lackluster stock price and poor performing portfolio.
FiercePharma · ByEric Palmer · 9 hours ago
Pfizer
In-depth coverage >
Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended ... Get straightforward advice on what’s really happening with the stock markets, direct to your inbox. Help yourself with our FREE email newsletter designed to …
Motley Fool UK · 15 hours ago
dividend yield